MX2020011398A - Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico. - Google Patents

Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico.

Info

Publication number
MX2020011398A
MX2020011398A MX2020011398A MX2020011398A MX2020011398A MX 2020011398 A MX2020011398 A MX 2020011398A MX 2020011398 A MX2020011398 A MX 2020011398A MX 2020011398 A MX2020011398 A MX 2020011398A MX 2020011398 A MX2020011398 A MX 2020011398A
Authority
MX
Mexico
Prior art keywords
crps
neridronic acid
administration
pain syndrome
complex regional
Prior art date
Application number
MX2020011398A
Other languages
English (en)
Inventor
Christa Kneip
Bernd Lange
Stephan Benay
Marielle Eerdekens
Sylvia Engelen
Susanne Thun
Original Assignee
Abiogen Pharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma Spa filed Critical Abiogen Pharma Spa
Publication of MX2020011398A publication Critical patent/MX2020011398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a ácido neridrónico para uso en un método para tratar síndrome de dolor regional complejo (CRPS) o dolor asociado con el CRPS, en donde el ácido neridrónico se administra intravenosamente en una o más dosis unitarias individuales cada una siendo administrada por al menos 4 horas. La invención se refiere, además, a ácido neridrónico para uso en un método para tratar CRPS de conformidad con la duración del CRPS en el paciente, a una dosificación particular de conformidad con la funcionalidad renal del paciente y a un kit para la administración de ácido neridrónico en los métodos inventivos.
MX2020011398A 2018-04-30 2019-04-30 Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico. MX2020011398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664496P 2018-04-30 2018-04-30
PCT/EP2019/061003 WO2019211261A1 (en) 2018-04-30 2019-04-30 Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid

Publications (1)

Publication Number Publication Date
MX2020011398A true MX2020011398A (es) 2020-11-24

Family

ID=66529985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011398A MX2020011398A (es) 2018-04-30 2019-04-30 Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico.

Country Status (7)

Country Link
US (1) US20190328755A1 (es)
EP (1) EP3787636A1 (es)
JP (1) JP2021522220A (es)
CN (1) CN112334139A (es)
CA (1) CA3097501A1 (es)
MX (1) MX2020011398A (es)
WO (1) WO2019211261A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2849758T3 (en) * 2012-05-14 2018-05-14 Antecip Bioventures Ii Llc COMPOSITIONS INCLUDING ZOLEDRONIC ACID OR RELATED COMPOUNDS TO RELIEVE INFLAMMATORY Pain and RELATED CONDITIONS
US9820999B2 (en) * 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
PL3206694T3 (pl) * 2014-10-15 2020-12-28 Abiogen Pharma Spa Zastosowanie kwasu nerydronowego lub jego soli w leczeniu osteoartrozy

Also Published As

Publication number Publication date
JP2021522220A (ja) 2021-08-30
EP3787636A1 (en) 2021-03-10
WO2019211261A1 (en) 2019-11-07
US20190328755A1 (en) 2019-10-31
CA3097501A1 (en) 2019-11-07
CN112334139A (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
HRP20110198T1 (hr) Indikacija doziranja progesterona u liječenju traumatske ozljede mozga
NZ598661A (en) Low frequency glatiramer acetate therapy
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022000143A (es) Metodos novedosos.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2020011398A (es) Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico.
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
MY187270A (en) Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor
MX2021003668A (es) Composición de ketamina para su uso en un método de tratamiento de la depresión por administración pulmonar.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
Zabolotskikh et al. Perioperative management of patients receiving long-term antithrombotic therapy. Clinical practice guidelines
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
Pollock et al. An Evaluation Of The Budget Impact Of The New 20% Subcutaneous Immunoglobulin (IG20GLY) For The Management Of Primary Immunodeficiency Diseases In Switzerland
Baquero-Salamanca Enoxaparin-sodium/rivaroxaban/warfarin
RU2011108787A (ru) Способ лечения больных красным плоским лишаем слизистой полости рта
Minford Protein-C
Delanaye et al. Compliance of the hemodialysis patient to the native vitamin D therapy